Trial Profile
An open-label, uncontrolled, multi-center study in pediatric patients with supraventricular tachyarrhythmia and low cardiac function (Heartful study)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs Landiolol (Primary)
- Indications Atrial fibrillation; Atrial flutter; Supraventricular tachycardia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Heartful
- Sponsors Ono Pharmaceutical
- 08 Dec 2021 Status changed from recruiting to completed.
- 02 Jun 2016 New trial record